FDA clears Momentis Surgical’s multiport surgical robot
July 23, 2026
Momentis Surgical (formerly Memic) announced today that it received FDA 510(k) clearance for the multiport configuration of its surgical robot.
Momentis Surgical (formerly Memic) announced today that it received FDA 510(k) clearance for the multiport configuration of its surgical robot.
Johnson & Johnson (NYSE:JNJ) announced today that it received FDA de novo authorization for its Ottava surgical robot system.
Philips (NYSE:PHG) today announced that it received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor.
Casana announced today that it launched the Smart Seat, a smart toilet seat capable of measuring a range of metrics.
BURLINGTON, Mass., July 20, 2026 /PRNewswire/ — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for C-1101, its lead investigational therapy for chronic painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica.
SEOUL, South Korea, July 21, 2026 /PRNewswire/ — Seegene, Inc. (“Seegene”), a global leader in molecular diagnostics, announced today that its U.S. subsidiary, Seegene USA, Inc. (“Seegene USA”), has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Allplex™ HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR assay designed to simultaneously detect multiple viral pathogens associated with clinically overlapping lesion presentations.
The technology offers a dual-sided design with a nonporous underside and porous polyethylene structure on other sides.
NEWNAN, Ga., July 17, 2026 /PRNewswire/ — Poriferous, LLC, a leading global manufacturer of SuᐧPor® craniomaxillofacial and patient-specific implants, has been awarded its patent for its innovative DuraBloc™ technology from the U.S. Patent and Trademark Office (USPTO), U.S. Patent No. 12,653,677, issued on June 16, 2026.
BOSTON, July 16, 2026 /PRNewswire/ — HoneyNaps, an AI-based sleep medicine company, today announced that SOMNUM V3.0, its AI diagnosis software for polysomnography (PSG) analysis, has received U.S. Food and Drug Administration (FDA) clearance under clearance number K253390.
The LightningWire system is designed to support transseptal access in procedures such as atrial fibrillation ablation, left atrial appendage closure and transcatheter mitral interventions.